Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

InvestingPro analysis reveals that DexCom maintains a healthy current ratio of 1.52 and operates with moderate debt levels, suggesting strong operational stability. DexCom faces what Piper Sandler ...

The research note pointed out that DexCom shares have recently declined despite the upcoming 15-day product cycle and revenue growth that should align more closely with the company’s healthy volume ...

As of October 30, 2025, the average one-year price target for DexCom is $102.13/share. The forecasts range from a low of $85.07 to a high of $126.00. The average price target represents an increase of ...